Related Experiment Video
Updated: Jan 5, 2026
06:04
Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.
Published on: March 6, 2018
17.5K
Medication-induced obstructive uropathy and hyperprolactinemia in a pediatric patient
Kwabena Nkansah-Amankra1, Sathyanarayan Sudhanthar1
1Department of Pediatrics and Human Development College of Human Medicine Michigan State University East Lansing MI USA.
Clinical Case Reports
|October 19, 2019
Summary
Hyperprolactinemia, often caused by pituitary tumors or stalk compression, requires ruling out hypothyroidism, renal failure, and drug interactions. Prolactin levels suggest the cause, but medication effects are key in polypharmacy patients.
Area of Science:
- Endocrinology
- Neuroendocrinology
Background:
- Hyperprolactinemia can stem from pituitary tumors or stalk compression, impacting dopamine levels.
- Diagnostic evaluation for hyperprolactinemia necessitates excluding hypothyroidism, renal failure, and drug interactions.
Observation:
- Elevated prolactin levels can indicate the underlying cause of hyperprolactinemia.
- Drug interactions are a crucial consideration, particularly in patients with multiple medications.
Findings:
- Pituitary tumors and stalk compression are common etiologies for hyperprolactinemia.
- Hypothyroidism, renal failure, and medication side effects must be systematically excluded.
Implications:
- Accurate diagnosis of hyperprolactinemia is essential for targeted treatment.
- Careful medication review is critical for managing drug-induced hyperprolactinemia.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
184
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
184
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
163
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
163
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
210
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
210
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.1K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.1K
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
227
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
227
01:29Drug Dosing: Infants and Children
224
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
224